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Sl~nffh:ant E n ~  of ~ 
Ultrasound4nduced Thromlmlys~ Using 
Per f luorocarbo~Exposed $onlc~ted Oext roN 
Albumin Ml~'obubblas 
Thomas Porter, RObert F. LeVean, Randy Fox, Alan K~csfeld, Feng XIo. 
Univers~ o~ Nebra~ Medlc~ Oente~. Omah~ Nebraska 
~n me presence of ~}Oh ~tens~y um.asound, mlcrolx~(MO) c~,ate (ex, 
pardi and collapse) a.~ release e ,erw which im been shown to ca~tyze 
vadot~ ~ and ct,,emic~ ~,;-~sass uch as ~ g'L). Since 
sonlcated per f luml~m' . -~q~ dextrose ~ (PESDA) is a slable 
form of MB, we r~l~41wslzed mat mey would be capable of enhandno thera- 
peu~ unmsound (TUS)~nducod TL  ~ t y ,  we reassured % c~ot ~ys~ 
(%CL) ~ equagy-slzed thromU (0.99 + 0.12 ndn~ams) ma~e from fre~h~/ 
drswn blood Inct~,~, for two houm and then e ~  In vflm to TUS (1.5 
Watts/cm~). The mmmbl were bathed m lout mlttglters (n,J) of er, he~ asflne 
(S), dn~se  |UK) |20,000 Unlls), PESOA {4 mr), or UK and PESDA com- 
bined (10,000 Units UK + 2 ml PESDA). A total of 96 separa~ san~ were 
~ompamd, Resu~ axe shown: 
U.~+$ US+UK US+ PF.SDA US + UK+ PESDA 
%C,L 254-16 49"4=8* 444-20" 69*9"  
• p < 0.0S oampmedto US + S, S, UK. e~l M~; "p  < O.05mmpmed ta ~. 
in Ihe absenco of TUS, PESDA producod no TL (3 d: 3%CL), and UK alone 
producod only 18 =t: 2%CL The signWcangy beltor TL sean with PESDA + UK 
+ US occulmd despite using only half the doses of UK and PESOA toat were 
usod when each agent was tested aicne. We conclude that (a) PESDA alone 
can slgniflcumly enhance TUS-inducod TL and 0a) g~ere appears to be an 
addtt~m thrombo~y1~ effect L,y adding ~ IJK and PES~A to T~S-tnducod 
tint ~ysis. 
~ O r a l  Conlvoh Cenlrallzed Clinic Ant icoagulat ion 
vs. lndlvMual Phys ldans  
Surash K. Daniel, Cindy O'Steen, An~e McGr~l, Robert H. Chapman. 
Kevfn R Browne, Watson C//n/c, Lake/and, FL 
The number of paSants maintained on chronic oraJ an~lat inn  with 
wadadn has rapidly increased over the past several years. Complic~Jons 
related to wa#drin use as well as thrombotic and embolic cornplk:~ons are 
directly related to maintaining the patJeflt in the therapeutic range as mea- 
sured by INR. Centralized marmgement of warfadn ~ ~ ev'~uated 
to detsn~ice It Iherapeutk: conlml of INR wzzs supedor Io indivtClual Id~tsician 
management. 
The mdy group was comprised of 100 patients conseat,~y chosan fnxn 
925 patients managed In a large anticoagulant (:link: (AC). To be included in 
the study group, each palJant had to be monltsred for at least throe monlhs 
by thefr individual i~/slclan and three months by ~ AC. Patients were 
classtfled loy reason for a~ta~ion  and by type of ph~n max~ 
their an~la l inn .  The reason for an~lat ion  was aldal f'~nllaSon 
(40 pts), valvular heml disease (n = 16), cardlomyopathy (n =8), PVD(n 
= 3), pulmonmy embolism (n = 4). coronaw artmy disease (n = 3), deep 
venous thrombosis (n - 8), CVA (n -- 9), TIA (n ,. 4), ~ group (n = 
5). Internists followed 44 patients, cardiologists 50 patients and surgeons 6 
pallents. IndMdual phys ic l~  patieofs were found ~ be out of g'ze 
1'nmapeuti~ NR range 47% ol the dine comp~'e~ s '~ 24% o! the l:m~++,.s 
I 1 ~  by llle anticoagulant clink: (p < 0.001). NO significant d'd~erance 
was found by physician specialty in ~menL  
We conclude that the anticoagulant clinic provides beUer control of wadadn 
lt,~'apy than icd~lual pl~ysldan ~ Given that better control 
mo(luces fewer coml~:ations, this form of antlcoagu~on management 
~apem pmfen~, 
~'~- ]  PFO Closure Prevent Recurrent Stroke TIA to  o r  
In Young Adults  
Joseph A. Dearanl, James J, Monis, Roger L Click, George W. Petty, Kent 
R. Bailey, Bijoy K. Iotandheda~ Mayo C//n/c, Roctms~, MN 
Whether sulgk:a] closure of patent 1oraman ova]e {PFO) in young aduils aftra 
cerebral ischemic events ixevento remmeme r mains ques~nable. EigMy- 
fivo pt less ~m age 50 (me~ 39 ~ 8 ~r) were m ~  idanmicd w"h 
stroke (n = 58) or TIA (N = 27) and .~ubsequant unequivocal demonstration 
of a PFO by I m n s ~  echo. Comoddd concrdions were abial fil~'l- 
lation (AF) in 2%, diabetes in 2%, hypertension in 16%, and deep venous 
g~ombas~s ~n 5%. Tma~nem was ~ (As~) or w..afadn (n - 59), m'~ 
A,'3A or warladn followed by PFO closure (n ,, 14), Ini1~al PFO closure (n - 
~0), and no therapy (n - 2). Operative moroUty and tug,amY of PFO c~osu~e 
were 0%. Pecurrent evants o¢omed in 11 pt without and 1 pt with PFO 
closure (mean foflow-up 2.9 4-1.9 yrs). Univariate proporSonal hazard (1=1t) 
analyses suggested the fogowing factors to be associated with recurrence 
dsk: ¢tmba as index ~ [hazard tati~ (HR) OA2., 70% confidence intewal 
(Ct) (0.23, 0.75~ p = 0.~4~; s ~  ~,~R 2.9 {1.49, 5.67) p ~- O 11}; AF [FiR 3.8 
(1.34,10.85) P = 0.20]. No PFO closure seemed to be associated w~th igher 
rectme¢¢e dsk ~R 32 (1.1, 9.1)], but these results eoul0 he ~ to 
cl~ance (p - 0.19). Them was no d'~ereme in recunenco risk wlth t=e of 
either ASP, or wadadn. We conclude, (i) the overall cumulative proba~'lity 
of having a recun'ent embotlc event with PFO is 0.20 at 5 years (CI.'0.08, 
0.30), (2) PFO closure may be associated wilh agmater tha~ 50% reducticn 
in mcurmn~ dsk, and ~3) su~ closm of PFO can be acco~ at 
r~nhllal dsk in yoan9 a~ms. 
[ '~- '2"~ Elfeets of  introducing Ulba-Low Do~e Warlarin 
and Aspldn on Fibdn D-Dtmer and 
Beta-Thromboglobulin as Markers o f  
I r ~ l m  " r l i - , rmn~f~ and Platelet 
Actival ion In Chronk= Alrla| Flbri l lMion 
Gregoiy Y.H. Up, Peck Un Up. John Zarifls. D~id Bareford. Gordon L.Ow~, 
R0bert Wagon. Gareth Beevem. ~ ~ of Meo~ne, C/~, 
Homo., B#m/ngham: Roy~ ur~vm,~, ~ un~ tong~o,, 
Chnmic affial ~ n  (AF) is an ardl~mla which is ~ with a. high 
dsk ol slmke. To detem~ne the elects olwadad~ and asp~in on 1~'ombo- 
genesis asd plate~t astiva~on in AF, we measured sequential changes in 
plasma fro~ D-dimer (an index of fibdn turnover and inVavascu~ throm- 
bogenesis, AGEN-EUSA) and beta-thmmboglobufin (p-TG, a measure of 
platelet actfv"atk~, AMERSHAM) in 51 ~ (34 male, 17 f~naic; mean 
age 70.4 ~ '~ + s.d. 7.~) with chronic AF before and at 2 and 6 weeks 
fo,ow~g rando~ to either Img wad~.dn or 300 ~ a~n (Ptmse 
I). NI patients smae man mrled on standam warladn therapy, ain~ng for a 
larger INR of 1.5-2.5 (Phase 2) with samples at 2 and 6 weeks attenNards. 
Pretras~em results were compan~ to 26 healthy conlrols in sinta mylhm 
(16 male, 10 female; mean age 72.7 years 4- 9.9) Basefine ( ~ )  
p-TG and ~ levels in pazients with AF were s~,drk;~,~;~ elev-aed com- 
pared to controls (p-TG: 181 vs91 ng/ml, ~ dilleranco 79 rtg/ml, paired 
W~oxon test, p < 0.001; D-dimen 220 x~s 100 ng/n~, median ~1R~ 106 
ng/rnl, p = 0,0001), In phase 1. there ~m no s ~  ct~ges ~n leveb 
of D.<~mer or ,8-TG, despito waffadn I mg :~r aspidn 300 rag. However, with 
~andard warfadn therapy (Phase 2), them was a ,mc~ction in nzed~n ~-TG 
at6~ (207 vs 172 ng/ml; p = 0.025) and a seque~ reduc~n in 
median ~ icvels, at 2 weeks (220 vs 139 ng/ml; p = 0.001) and at 
6 weeks (220 vs 110 rig/rid; p < 0.001 ) when compared t~ baseline levels. 
Conc~us/on - -  ~ w11h AF havo fn(='eased inlmvascular lhmmboge- 
nes~ an~ p~d,~st activ-aino, as indcatsd by the high ~ and A-TG, 
whan compared to pa~Bnts in sinus d~thm, tntroducl~an of ul~a-icw d~se 
(1 rag) wadadn or aspidn 200 mg does not s '~ l ly  a!ter these ~ ,  
~lthough conventional warfadn therapy (target INR 1.5-2.5) reduces p-TG 
D-dimer levels. This is o0nsistont w~lh the beneficial effect of warfadn in 
weverdJng stroke in pa~ml:s with atrial ~] l~t~n. 
Inh i lb~on o f  Growth  Phammcr j log ic  Myocyte  
Wednesday, March 27, 1996, 3:00 p.m.--5:00 p.m. 
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1• .• -99  ACE inhlbHom Induce in the Vascular ~.optos~ Wag: Evlderce From Rat CarotM Ar te~ and 
Hunmn A ~  Samples 
w~ang Heube~r ~, ~ BaL.-~_~L ~ tn~n~ ~ne f, 
Univ~r~ of Munich, C-en~, ' Oba Ge~ An~, Wehr, R~G 
Recent ~P.hnal dr:Lta have shown that ACE int~3itms (after a suWident Ixelmat- 
me, t perkxl} suRare~ neointima formaticn ~n ~qZieed rat camtld an'erles. We 
hypolNzed gmt ACE ichP~on; (AI) curt induco ~3optosts and g~'mbY modu- 
late the re~pa,-,sh~,-,,~.:, of ~ smoe+h muscle csCts (SMCs) to r:~ltogen~c 
and rn im~¥ stlmuS. 7/14 Sixague Dawley r~ds (350 O) were treated wilh 
the Albenazel~il (10 mg/kg p.o.; GPua~,,~; Giba Geigy) for 14 d.ays and then 
sacdfled. Mmplzon~bic an,~ysts of sedal camtld sectkms stzo,'~d a mean 
coll (;m,..sity of 3817:1:232 cegs/mm2 (x :t: SO) for AI rats, and 4208 ";" 697 
co~ fo.- ~ animals (p = 0.13). TUNEL testing ~ a hi0h pro- 
man~ diy (p < 0.01 ) lower slgnallin~ (6 :~: 4%) was obs~ved In control rats. In 
grin to ~ the f~ctional significance of this finding, we used a cell 
culture ~ to stimulate SMO outgrowg- (i.e. ~ and pm,feraticn). 
Notably, AI ~ explants exhg~ed SMC outgrowth after 4.2 :E 0A days 
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